Effect of ticagrelor and clopidogrel on adverse cardiac events in patients with ACS after PCI

JIN Chun; SONG Ying; ZU Wu; LI Tingting

doi:10.3969/j.issn.1671-6450.2017.05.001

Abstract：Objective To observe the effect of ticagrelor and clopidogrel on ischemic events in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods A total of 96 cases with ACS successfully undergoing PCI between July 2014 and August 2015 were enrolled in the study. They were divided into the clopidogrel treatment group (control group) and ticagrelor treatment group (observation group) by the random number table method, 48 cases in each group. The control group was treated with aspirin and clopidogrel while the observation group was treated with aspirin and ticagrelor. Before treatment, 24 h, 1 week and 1 month after treatment, the maximum platelet aggregation rates (MPAR), P2Y12 reaction unit (PRU), adverse reactions in the two groups during treatment, adverse cardiac events and bleeding events within six months were observed and compared between the two groups. Results There were significant differences in MPAR, PRU and cTnI within group, at different time points and between groups at different time points (within group:F=4.587,F=2.841,F=3.651,P<0.05, at different time points:F=16.254,F=12.854,F=15.021,P<0.05,between groups at different time points:F=13.578,F=10.149,F=12.574,P<0.05).In six months of follow up, the incidence of ischemic events was significantly lower in the observation group than the control group (8.33% vs 27.08%) (χ2=4.575,P=0.032). There was no significant difference in the incidence of bleeding events and adverse reactions between the two groups (χ2=0.753,χ2=0.049,P=0.386,P=0.852). Conclusion Compared with clopidogrel, ticagrelor can better inhibit platelet aggregation in patients with ACS after PCI, reduce the incidence of adverse cardiovascular events, without increasing adverse reactions.